EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comprehensive analysis reveals prognostic gene set that could impacts the response to chemotherapy and immunotherapy outcomes in malignant pleural mesothelioma

Jun Li, Hongye He, Yutao Zhang, Muhammad Salman Azhar, Yongxiang Wang

Clinical and Experimental Medicine · 2025

DOI: 10.1007/s10238-025-01949-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2025. Verfasst von Jun Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Zigong First People's Hospital, Zigong, Sichuan Province, China. Hauptthemen laut MEDLINE: Mesothelioma, Malignant, Immunotherapy, Pleural Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant pleural mesothelioma (MPM) is a rare but aggressive thoracic malignancy primarily linked to asbestos exposure. Despite advances in research, the prognosis of MPM remains poor, and there is a lack of efficient and precise prognostic assessment tools. Its insidious onset, limited treatment options, and high resistance to therapy contribute to poor clinical outcomes and underscore the urgent need for reliable prognostic biomarkers. To address this gap, we integrated multi-omics data to identify a prognostic gene set for MPM and subsequently developed a prognostic model aiming to improve the clinical outcomes of this disease. Transcriptomic data from TCGA were used to identify genes related to prognosis and tumor stage in malignant pleural mesothelioma (MPM), followed by construction of a prognostic model via LASSO-Cox regression and external validation using a GEO dataset. The model was then integrated with DNA methylation and SNP data for GO enrichment analysis. Chemotherapy drug IC50 data from MPM cell lines were correlated with model gene expression to evaluate associations between risk scores and drug sensitivity, which were further validated using TCGA clinical response data. Finally, the model's impact on the immune microenvironment was assessed using single-cell RNA-seq data, and its predictive value for immunotherapy response was validated in an independent MPM immunotherapy cohort. Our novel prognostic model demonstrated consistent performance in both the training and validation cohorts. Patients with high-risk scores had poorer outcomes, with AUC values exceeding 0.8 and reaching 0.9 for 3 year survival prediction. The risk score accurately reflected biological processes such as tumor proliferation and metastasis in mesothelioma. It was also closely associated with clinical responses to radiotherapy and chemotherapy, with low-risk patients showing greater sensitivity and lower drug IC50 values. Additionally, the risk score correlated positively with tumor immune activity and was predictive of immunotherapy response. In conclusion, our prognostic model shows strong and reliable predictive power for patient survival and treatment response in malignant pleural mesothelioma. It not only reflects key tumor biological processes but also serves as a potential tool for guiding personalized therapy, including chemotherapy, radiotherapy, and immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesothelioma, MalignantImmunotherapyPleural NeoplasmsBiomarkers, TumorLung NeoplasmsMesotheliomaHumansPrognosisFemaleMaleTumor MicroenvironmentGene Expression Regulation, NeoplasticGene Expression ProfilingTranscriptomeDNA MethylationCell Line, TumorAntineoplastic AgentsTreatment OutcomeMiddle Aged

Stichwörter der Autor:innen

ChemotherapyMalignant pleural mesotheliomaPrognosisTumor immunology

Substanzen

Biomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Nursing, Zigong First People's Hospital, Zigong, Sichuan Province, China.
  • Department of General Surgery, Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
  • Department of General Surgery, Ward 4, The fourth hospital of changsha, Changsha, China.
  • Department of General Surgery, Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China. drsalmanazhar93@gmail.com.
  • Department of General Surgery, Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China. 228202102@csu.edu.cn.

Zitieren

APA

Li, J., He, H., Zhang, Y., Azhar, M. S., & Wang, Y. (2025). Comprehensive analysis reveals prognostic gene set that could impacts the response to chemotherapy and immunotherapy outcomes in malignant pleural mesothelioma. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-025-01949-9

Vancouver

Li J, He H, Zhang Y, Azhar MS, Wang Y. Comprehensive analysis reveals prognostic gene set that could impacts the response to chemotherapy and immunotherapy outcomes in malignant pleural mesothelioma. Clinical and Experimental Medicine. 2025. doi:10.1007/s10238-025-01949-9

BibTeX
@article{Li2025,
  author = {Li, Jun and He, Hongye and Zhang, Yutao and Azhar, Muhammad Salman and Wang, Yongxiang},
  title = {Comprehensive analysis reveals prognostic gene set that could impacts the response to chemotherapy and immunotherapy outcomes in malignant pleural mesothelioma},
  journal = {Clinical and Experimental Medicine},
  year = {2025},
  doi = {10.1007/s10238-025-01949-9}
}
Kostenlos starten →